3[2]Slavin S, Naparstek E, Nagler A, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alterative to conventional bone marrow transplantation with lethal cytoreductive for treatment of malignant and nonmalignant hematologic disease[J]. Blood, 1998,91:756-763.
4Gregory SA,Vose J,Modiano M ,et al. Mitoxantrone and fludarabine in the treatment of patients with non-Hodgkin's lymphoma failing primary therapy with a doxorubicinor mitoxantrone-containing regimen[J]. Leuk Lymphoma,2001,40(3-4) : 315.
5Mclaughin P, Hagemeister FB, Romaguera JE, et al. Fludarabine mitoxantrone, and dexamethasone., an effective new regimen for indolent lymphoma[J]. J Clin Oncol,1996,14(4) : 1262.
6Santini G,Nati S,Spriano M,et al. Fludarabine in combination with cyclophosphamide or with cyclophosphamide plus mitoxantrone for relapsed or refractory low-grade non-Hodgkin's lymphoma [J]. Haematologica, 2001,86(3) :282.
7Herold M, Sacchi S, Hieke K. The cost of treating relapsed indolent non-Hodgkin's lymphoma in an international setting: retrospective analysis of resource use[J].Haematologica,2002,87(7) : 719.
8张之南.血液病诊断及疗效标准[M].北京：科学出版社,1999.270-271.
9Lamanna N, Weiss M. Purine analogs in leukemia. Adv Pharmacol,2004, 51:107-125.
10Milligan DW, Wheatley K, Burnett AK. Fludarabine, cytosine arabiuoside, granulocyte-colony stimulating factor with or without idarubicin in the treatment of high risk acute leukaemia or myelodysplastic syndromes. Br J Haematol, 2004,127:238-239.
